Short duration infusion for treatment of Follicular Lymphoma

COVID-19 update:

In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
James Mason, M.D.
The purpose of this study is to test the safety and effectiveness of a short duration infusion (90 minute infusion) of obinutuzumab in patients who have previously untreated advanced follicular lymphoma. Patients in this study will receive obinutizumab along with chemotherapy.

Inclusion Criteria

  • Be 18 years of age or older
  • Have previously untreated Stage III or IV follicular lymphoma or Stage II bulky disease
  • Have histologically documented CD-20-positive follicular lymphoma

Exclusion Criteria

  • Have relapsed / refractory or Grade IIIb follicular lymphoma
  • Have had prior treatment for follicular lymphoma with chemotherapy, radiotherapy, or immunotherapy
  • Have a history of anti-CD20 antibody therapy
  • Be pregnant, breastfeeding or planning on becoming pregnant

Additional Info

  • All treatments and physician visits will take place at Scripps Clinic Torrey Pines.
  • Study participation is expected to last up to 2.75 years

Contact Info:

  • Gail Moore, RN, CCRC
  • 858-554-8365